These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24085042)

  • 1. Adherence to ustekinumab in psoriasis patients.
    Sandoval LF; Huang KE; Feldman SR
    J Drugs Dermatol; 2013 Oct; 12(10):1090-2. PubMed ID: 24085042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
    Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
    J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis.
    Chang S; Chambers CJ; Liu FT; Armstrong AW
    Dermatol Online J; 2015 Jul; 21(7):. PubMed ID: 26436967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
    Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
    J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
    Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
    Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
    Papp KA; Griffiths CE; Gordon K; Lebwohl M; Szapary PO; Wasfi Y; Chan D; Hsu MC; Ho V; Ghislain PD; Strober B; Reich K; ; ;
    Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
    Kimball AB; Papp KA; Wasfi Y; Chan D; Bissonnette R; Sofen H; Yeilding N; Li S; Szapary P; Gordon KB;
    J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1535-45. PubMed ID: 23279003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
    Reich K; Schenkel B; Zhao N; Szapary P; Augustin M; Bourcier M; Guenther L; Langley RG
    J Dermatolog Treat; 2011 Dec; 22(6):337-47. PubMed ID: 21034290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris.
    Clemmensen A; Spon M; Skov L; Zachariae C; Gniadecki R
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1037-40. PubMed ID: 21108668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.
    Gisondi P; Conti A; Galdo G; Piaserico S; De Simone C; Girolomoni G
    Br J Dermatol; 2013 May; 168(5):1124-7. PubMed ID: 23320916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety of ustekinumab for psoriasis.
    Kumar N; Narang K; Cressey BD; Gottlieb AB
    Expert Opin Drug Saf; 2013 Sep; 12(5):757-65. PubMed ID: 23745965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis.
    Morales-Múnera C; Vilarrasa E; Puig L
    Br J Dermatol; 2013 Apr; 168(4):820-4. PubMed ID: 23210683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
    Doshi JA; Takeshita J; Pinto L; Li P; Yu X; Rao P; Viswanathan HN; Gelfand JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1057-1065.e4. PubMed ID: 26946986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.
    Patsatsi A; Kyriakou A; Sotiriadis D
    J Dermatolog Treat; 2013 Apr; 24(2):96-100. PubMed ID: 21797806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of ustekinumab in psoriasis.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Mar; 12(3):317-20. PubMed ID: 23545915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
    Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
    Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab improves psoriasis without suppressing tumor antigen-specific cytotoxic T lymphocytes.
    Narita M; Nishizawa Y; Iwaya S; Oiwa E; Iwabuchi M; Uchiyama T; Matsuyama A; Masuko M; Takahashi M
    Int Arch Allergy Immunol; 2014; 165(1):52-60. PubMed ID: 25342444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two Greek patients from the psoriasis hospital-based clinic.
    Papadavid E; Ferra D; Koumaki D; Dalamaga M; Stamou C; Theodoropoulos K; Rigopoulos D
    Dermatology; 2014; 228(2):107-11. PubMed ID: 24504077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.